2seventy bio-partnered Abecma (idecabtagene vicleucel) is already approved as a fourth-line or later therapy for the blood cancer, and the KarMMa-3 study is designed to support second or third ...

Abecma (idecabtagene vicleucel) is a brand-name infusion prescribed for multiple myeloma in certain adults. Abecma is not known to interact with other medications or supplements. But it can ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered cancer cell therapy Abecma as that product faces headwinds in a ...

The adjustment comes after Bristol Myers (NYSE:BMY) Squibb (BMS) reported fiscal year 2024 revenues for Abecma, a drug commercialized in partnership with 2Seventy Bio. The reported revenue of $242 ...

The FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat the disease. Abecma’s review was delayed after the FDA ...

They co-developed Abecma (idecabtagene vicleucel), a BCMA-targeted chimeric antigen receptor (CAR)-T cell therapy for multiple myeloma, which secured US Food and Drug Administration (FDA ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for ...

He noted that the company's focus on Abecma has positioned them to potentially reach quarterly breakeven by the end of 2025. The company's financial position includes approximately $184 million in ...

"2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure and focus solely on Abecma," said Chip Baird, chief executive officer, 2seventy bio.

2seventy bio investors were understandably happy this past week when Bristol Myers Squibb (BMS) agreed to acquire its partner in developing the blockbuster multiple myeloma drug Abecma ...

Net cash burn of $9 million in the fourth quarter of 2024; path to quarterly breakeven by the end of 2025 2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene ...